Study identifier:D8330C00003
ClinicalTrials.gov identifier:NCT05737940
EudraCT identifier:N/A
CTIS identifier:2022-502382-25-00
A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)
Pulmonary Hypertension (World Health Organization Group 2)
Phase 2
No
AZD3427, Placebo
All
220
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD3427 Dose A The participants will receive single dose of AZD3427 Dose A every 2 weeks for 24 weeks from Day 1 to Day 155. | Drug: AZD3427 The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks. |
Experimental: AZD3427 Dose B The participants will receive single dose of AZD3427 Dose B every 2 weeks for 24 weeks from Day 1 to Day 155. | Drug: AZD3427 The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks. |
Experimental: AZD3427 Dose C The participants will receive single dose of AZD3427 Dose C every 2 weeks for 24 weeks from Day 1 to Day 155. | Drug: AZD3427 The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks. |
Placebo Comparator: Placebo The participants will receive single dose placebo every 2 weeks for 24 weeks from Day 1 to Day 155. | Drug: Placebo The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks. |